Literature DB >> 8363350

Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices.

B D Pate1, T Kawamata, T Yamada, E G McGeer, K A Hewitt, B J Snow, T J Ruth, D B Calne.   

Abstract

Striatal 18F-6-fluorodopa (FD) uptake constants were measured by positron emission tomography in (1) normal cynomolgus monkeys and (2) a series of cynomolgus and rhesus monkeys that had received intracarotid infusions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). After the animals were killed, the number and average size of dopaminergic neurons in the substantia nigra pars compacta were measured. Striatal levels of dopamine and its metabolites, and the striatal activities of the dopaminergic synthetic enzymes, were also determined. The striatal FD uptake constants showed highly significant positive correlations with both number and size of dopaminergic neurons, indicating atrophy of surviving neurons in MPTP-treated animals. The uptake constants also showed significant positive correlations with striatal levels of dopamine, total catecholamines, and the activities of the synthetic enzymes. Both histochemical and biochemical data on tyrosine hydroxylase suggested some contralateral enzyme loss in these MPTP-treated monkeys, as well as decreased enzyme activity in surviving neurons on the lesioned side. However, residual enzyme activities were apparently not rate limiting to striatal FD uptake. It is concluded that PET-FD measurements by positron emission tomography provide a good index of the integrity of the nigrostriatal pathway.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8363350     DOI: 10.1002/ana.410340306

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  22 in total

Review 1.  Neuroimaging biomarkers for Parkinson disease: facts and fantasy.

Authors:  Joel S Perlmutter; Scott A Norris
Journal:  Ann Neurol       Date:  2014-11-07       Impact factor: 10.422

Review 2.  Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases.

Authors:  Lisa M Kosloski; Duy M Ha; Jessica A L Hutter; David K Stone; Michael R Pichler; Ashley D Reynolds; Howard E Gendelman; R Lee Mosley
Journal:  J Neurochem       Date:  2010-05-26       Impact factor: 5.372

3.  Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism.

Authors:  Timothy J Collier; Jack Lipton; Brian F Daley; Stephane Palfi; Yaping Chu; Caryl Sortwell; Roy A E Bakay; John R Sladek; Jeffrey H Kordower
Journal:  Neurobiol Dis       Date:  2007-01-23       Impact factor: 5.996

Review 4.  Neuroimaging in Parkinson's disease.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2004-04

5.  (18)F-DOPA PET with and without MRI fusion, a receiver operator characteristics comparison.

Authors:  Aaron F Struck; Lance T Hall; Joanna E Kusmirek; Catherine L Gallagher; John M Floberg; Christine J Jaskowiak; Scott B Perlman
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-10-15

6.  Ventral striatal prediction error signaling is associated with dopamine synthesis capacity and fluid intelligence.

Authors:  Florian Schlagenhauf; Michael A Rapp; Quentin J M Huys; Anne Beck; Torsten Wüstenberg; Lorenz Deserno; Hans-Georg Buchholz; Jan Kalbitzer; Ralph Buchert; Michael Bauer; Thorsten Kienast; Paul Cumming; Michail Plotkin; Yoshitaka Kumakura; Anthony A Grace; Raymond J Dolan; Andreas Heinz
Journal:  Hum Brain Mapp       Date:  2012-02-17       Impact factor: 5.038

7.  Pathophysiology of manganese-associated neurotoxicity.

Authors:  Brad A Racette; Michael Aschner; Tomas R Guilarte; Ulrike Dydak; Susan R Criswell; Wei Zheng
Journal:  Neurotoxicology       Date:  2011-12-21       Impact factor: 4.294

8.  Validation of nigrostriatal positron emission tomography measures: critical limits.

Authors:  Morvarid Karimi; LinLin Tian; Christopher A Brown; Hubert P Flores; Susan K Loftin; Tom O Videen; Stephen M Moerlein; Joel S Perlmutter
Journal:  Ann Neurol       Date:  2013-02-19       Impact factor: 10.422

9.  Plasma apolipoprotein A1 as a biomarker for Parkinson disease.

Authors:  Judy K Qiang; Yvette C Wong; Andrew Siderowf; Howard I Hurtig; Sharon X Xie; Virginia M-Y Lee; John Q Trojanowski; Dora Yearout; James B Leverenz; Thomas J Montine; Matt Stern; Susan Mendick; Danna Jennings; Cyrus Zabetian; Ken Marek; Alice S Chen-Plotkin
Journal:  Ann Neurol       Date:  2013-08-06       Impact factor: 10.422

10.  Clinical and [18F] dopa PET findings in early Parkinson's disease.

Authors:  P K Morrish; G V Sawle; D J Brooks
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-12       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.